Rx N115 Nonsteroidal Nasal Spray has demonstrated consistent efficacy with 2,300+ US Clinical Trial Patients and 1,000+ Chinese Clinical Trial Patients with no known side effects for all lung and sinus diseases tested including patients with Chronic Congestion and Coughing, COPD, Asthma, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Allergic Rhinitis, Chronic Rhinitis, Sinusitis, and the Flu.
EmphyCorp has Completed successful Phase III Clinical Trials in patients with Pulmonary Fibrosis, and in patients with Idiopathic Pulmonary Fibrosis (which demonstrated statistically significant reduction in coughing with Improved Lung Function, including increased Oxygen levels and decreased Shortness of Breath in all patients). Phase III clinical trials were also completed for patients with COVID-19 (significantly reduced COVID infections), and in Long COVID patients (Long Haulers), which significantly reduced Symptoms associated with Long COVID.
